Copenhagen, Denmark, September 10, 2026
H. Lundbeck A/S has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart, the company’s investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, for the treatment of endogenous Cushing’s syndrome. The regulatory designation recognizes the potential of asedebart to address an uncommon and serious endocrine disorder characterized by prolonged exposure to excessive cortisol. The milestone supports Lundbeck’s ongoing development of asedebart as a potential targeted treatment for patients with endogenous Cushing’s syndrome, an area where additional therapeutic options remain needed.
Lundbeck Advances Asedebart for Cushing’s Syndrome
Asedebart is an investigational monoclonal antibody designed to selectively bind and neutralize ACTH, a hormone that stimulates the adrenal glands to produce cortisol. In endogenous Cushing’s syndrome, excessive cortisol production is driven by abnormal activation of the hypothalamic-pituitary-adrenal axis, with ACTH playing an important role in regulating adrenal cortisol production in many forms of the disease. By targeting ACTH, asedebart is being developed with the aim of reducing the hormonal signaling that contributes to excess cortisol production. This mechanism could potentially provide a more targeted approach to managing the underlying hormonal pathway rather than focusing solely on the downstream effects of elevated cortisol. Cushing’s syndrome can cause substantial and potentially serious health consequences when excessive cortisol exposure persists. Patients may experience weight gain, muscle weakness, hypertension, glucose abnormalities, osteoporosis and increased cardiovascular risk, among other complications. The disease can also significantly affect quality of life. The current treatment landscape includes surgery, medications that inhibit cortisol production or action, and other interventions depending on the underlying cause. However, not all patients achieve adequate disease control, creating a continuing need for new treatment approaches.
FDA Orphan Drug Designation Supports Development
The FDA’s Orphan Drug Designation is intended for therapies being developed for rare diseases or conditions affecting relatively small patient populations in the United States. The designation can provide eligible development programs with incentives designed to encourage research into treatments for rare diseases, including potential tax benefits, clinical research support and eligibility for certain regulatory incentives. For Lundbeck, the designation represents an important regulatory milestone for asedebart as the company continues its clinical development program. Importantly, Orphan Drug Designation is not an approval of the medicine and does not establish its safety or efficacy. Asedebart remains an investigational therapy and will require successful clinical development and regulatory review before it could potentially be marketed. The designation reflects the FDA’s recognition that endogenous Cushing’s syndrome represents a rare condition for which development of additional therapeutic options may provide meaningful benefits to patients. Lundbeck is evaluating asedebart as part of its broader strategy to develop treatments for neurological and related serious diseases, while expanding its research activities into areas with significant unmet medical needs.
Advertisement
Asedebart Targets ACTH-Cortisol Pathway
The scientific rationale for asedebart is based on the central role of the ACTH-cortisol pathway in endogenous Cushing’s syndrome. ACTH is produced by the pituitary gland and normally stimulates the adrenal glands to release cortisol. When ACTH signaling becomes excessive or dysregulated, it can contribute to abnormal cortisol production. Asedebart is designed to bind to ACTH and prevent it from activating its receptor on adrenal cells. By reducing ACTH-driven signaling, the investigational antibody is intended to potentially decrease adrenal cortisol production. The approach could be particularly relevant for patients whose Cushing’s syndrome is associated with ACTH-dependent disease, although clinical studies will be required to establish which patient populations may benefit most from treatment. The potential clinical value of the therapy will ultimately depend on whether ACTH neutralization can produce sustained control of cortisol levels while maintaining an acceptable safety profile. Future clinical data will therefore be important for assessing pharmacological activity, dose selection, safety and clinical efficacy. The FDA’s orphan designation adds regulatory recognition to Lundbeck’s development program and highlights the company’s efforts to advance an investigational therapy for a rare endocrine disorder. Further clinical research will determine whether asedebart can progress from an experimental anti-ACTH antibody into a viable treatment option for patients living with endogenous Cushing’s syndrome.
Source: Lundbeck press release
